Track argenx SE — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

argenx SE ARGX.BR · Stock Open argenx SE in new tab

733.20 EUR
P/E
32.39
EPS
22.49
P/B
6.06
ROE
23.64
Beta
-0.04
Target Price
1022.41 EUR
argenx SE logo

argenx SE

🧾 Earnings Recap – Q2 2026

Shares gained 6.1% following strong revenue growth and expanding market penetration, driven primarily by robust product sales and strategic investments in late-stage pipeline programs.

  • Q2 product net sales reached $1.5 billion, up 60% year-over-year and 17% quarter-over-quarter.
  • U.S. sales grew 15% quarter-over-quarter, with Japan sales increasing 55%, partly boosted by a one-off $25 million distribution model change.
  • Operating expenses rose by $129 million sequentially to $1 billion, reflecting deliberate investment in R&D and commercialization to support pipeline expansion.
  • Operating profit increased 146% year-over-year to $494 million, with a tax rate of 11%.
  • Cash balance strengthened to $5.2 billion, supporting ongoing capital allocation toward sustained long-term growth.
📅
Loading chart...
Key Metrics
Earnings dateMarch 4, 2027
P/E32.39
EPS22.49
Book Value120.14
Price to Book6.06
Debt/Equity0.56
% Insiders0.009%
Growth
Revenue Growth0.59%
Earnings Growth0.95%
Estimates
Forward P/E22.70
Forward EPS32.08
Target Mean Price1022.41

DCF valuation

Model fair value for argenx SE (ARGX.BR)
Result
Sign in to run the valuation for ARGX.BR.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
15 analysts · consensus Strong buy · mean target 1022.41 EUR (low 776.39, high 1249.22) · as of 12 Oct 2026
Low 776.39
Mean 1022.41
High 1249.22
Price 733.20
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

argenx SE Logo argenx SE Analysis (ARGX.BR)

Netherlands Health Care Official Website Stock

Is argenx SE a good investment? argenx SE (ARGX.BR) is currently trading at 733.20 EUR. Market analysts have a consensus price target of 1022.41 EUR. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 32.39. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: argenx SE is expected to release its next earnings report on March 4, 2027. The market consensus estimate for Forward EPS is 32.08.

Investor FAQ

Does argenx SE pay a dividend?

No, it does not currently pay a dividend.

What asset class is argenx SE?

argenx SE is classified as a Stock. You can compare it against 10 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 4, 2027. The company currently has a trailing EPS of 22.49.

Company Profile

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Exchange Ticker
VIE (Austria) ARGX.VI
BRU (Belgium) ARGX.BR
BER (Germany) 1AE.BE
FRA (Germany) 1AE.F
MUN (Germany) 1AE.MU
STU (Germany) 1AE.SG
FRA (Germany) 1AEA.F
STU (Germany) 1AEA.SG
SAO (Brazil) A1RG34.SA
PNK (United States) ARGNF
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion